Table 3.
Results of efficacy analysis at last follow-up
| End Point | NIAT-Rituximab Group, n=37 | NIAT Group, n=38 | P Value |
|---|---|---|---|
| Remission, complete and partiala | 24 (64.9; 49.5 to 80.2) | 13 (34.2; 19.1 to 49.3) | <0.01 |
| Protein-to-creatinine ratio, mg/g | 2194.8 (1309.8–5310.0) | 4701.1 (2027.8–8265.3) | 0.02 |
| Serum albumin, g/L | 32 (26–35) | 27 (20–30) | 0.03 |
| Serum creatinine, μmol/L | 101 (87–135) | 97.2 (78.5–133.5) | 0.50 |
| eGFR, ml/min per 1.73 m2 | 61.1 (48.7–83.4) | 73.1 (50.4–90.5) | 0.48 |
Data are shown as n (%; 95% CI) or median (IQR). Data were recorded before any potential modification of treatment assigned at randomization (modification of initial immunosuppressive treatment in the NIAT-rituximab group or addition of any immunosuppressive treatment in the NIAT group).
a
Complete and partial remissions were defined according to 2012 KDIGO criteria on the basis of proteinuria.